Ikarian Capital, LLC Gilead Sciences, Inc. Call Options Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 12, 2022	SELL	$57.72 - $65.01 $10.5 Million - $11.8 Million	-181,300 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$57.92 - $72.58 $10.5 Million - $13.2 Million	181,300 New	181,300 $10.8 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $5.42 Million - $5.84 Million	-80,000 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$63.47 - $69.35 $23.1 Million - $25.2 Million	-363,600 Reduced 81.97%	80,000 $5.51 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $8.62 Million - $9.83 Million	143,600 Added 47.87%	443,600 $28.7 Million
Q4 2020 Feb 12, 2021	BUY	$56.65 - $64.55 $2.83 Million - $3.23 Million	50,000 Added 20.0%	300,000 $17.5 Million
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $15.7 Million - $20.1 Million	-250,000 Reduced 50.0%	250,000 $18.7 Million
Q4 2019 Jan 31, 2020	BUY	$61.62 - $67.78 $30.8 Million - $33.9 Million	500,000 New	500,000 $32.5 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.